DaxibotulinumtoxinA
| Names | |
|---|---|
| Trade names | Daxxify |
| Other names | Daxi, daxibotulinumtoxinA-lanm |
| Clinical data | |
| Drug class | Botulinum toxin |
| Main uses | Wrinkles between the eyebrows[1] |
| Side effects | Headache, eyelid dropping, trouble moving the face, breathing problems[1] |
| WHO AWaRe | UnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽ |
| Routes of use | Intramuscular |
| Duration of action | Up to 6 months[2] |
| Legal | |
| License data | |
| Legal status | |
DaxibotulinumtoxinA, sold under the brand name Daxxify, is a medication used to improvement the appearance of wrinkles found between the eyebrows.[1] It may also be given for cervical dystonia.[2] It is given by injection into muscle.[1] Effects may last for up to 6 months.[2]
Common side effects include headache, eyelid dropping, and trouble moving the face.[1] Other side effects may include swallowing or breathing problems.[1] It is a botulinum toxin A which inhibits acetylcholine release and is a neuromuscular blocking agent.[1]
DaxibotulinumtoxinA was approved for medical use in the United States in 2022.[1] It is a commercial competitor to Botox.[3]
References
- 1 2 3 4 5 6 7 8 9 "Daxxify- botulinum toxin type a injection, powder, lyophilized, for solution". DailyMed. 19 September 2022. Archived from the original on 28 September 2022. Retrieved 27 September 2022.
- 1 2 3 Solish, N; Carruthers, J; Kaufman, J; Rubio, RG; Gross, TM; Gallagher, CJ (December 2021). "Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A.". Drugs. 81 (18): 2091–2101. doi:10.1007/s40265-021-01631-w. PMID 34787840.
- ↑ "U.S. FDA declines to approve Revance's frown-line treatment". Reuters. 15 October 2021. Archived from the original on 17 January 2022. Retrieved 13 December 2022.
External links
| Identifiers: |
|
|---|
- F.D.A. OKs Daxxify, an Anti-Wrinkle Drug and Botox Competitor Archived 2022-10-03 at the Wayback Machine
- Carruthers JD, Fagien S, Joseph JH, Humphrey SD, Biesman BS, Gallagher CJ, et al. (January 2020). "DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2)". Plastic and Reconstructive Surgery. 145 (1): 45–58. doi:10.1097/PRS.0000000000006327. PMC 6940025. PMID 31609882.
- Solish N, Carruthers J, Kaufman J, Rubio RG, Gross TM, Gallagher CJ (December 2021). "Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A". Drugs. 81 (18): 2091–2101. doi:10.1007/s40265-021-01631-w. PMC 8648634. PMID 34787840.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.